GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » Deferred Policy Acquisition Costs

Marvel Biosciences (TSXV:MRVL) Deferred Policy Acquisition Costs


View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Marvel Biosciences Business Description

Industry
Traded in Other Exchanges
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
Executives
Joseph Roderick Matheson Director, Senior Officer
Neil Allan Johnson Director
Jacqueline Groot Senior Officer